Dr. Rotkowitz on the Dabrafenib/Trametinib Combination

Michael Rotkowitz, MD
Published: Thursday, May 17, 2012

Michael Rotkowitz, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses bypassing resistance in patients with melanoma that are receiving vemurafenib.

Rotkowitz notes that melanoma has been at the forefront of new pharmaceutical developers, in recent years. This includes the immunotherapy ipilimumab and the BRAF inhibitor vemurafenib. However, in some cases the responses to these medications will only last a few months before resistance is acquired. This makes studying the mechanisms of resistance very important.

In many cases, tumors bypass BRAF inhibition using the MEK pathway. This resistance pathway established the rational behind the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib.

Rotkowitz notes that early data has shown that the combination helped control the tumor and even limited the side effects that are normally associated with BRAF inhibition.

<<< View more from the 2012 ASCO Conference

Michael Rotkowitz, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses bypassing resistance in patients with melanoma that are receiving vemurafenib.

Rotkowitz notes that melanoma has been at the forefront of new pharmaceutical developers, in recent years. This includes the immunotherapy ipilimumab and the BRAF inhibitor vemurafenib. However, in some cases the responses to these medications will only last a few months before resistance is acquired. This makes studying the mechanisms of resistance very important.

In many cases, tumors bypass BRAF inhibition using the MEK pathway. This resistance pathway established the rational behind the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib.

Rotkowitz notes that early data has shown that the combination helped control the tumor and even limited the side effects that are normally associated with BRAF inhibition.

<<< View more from the 2012 ASCO Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x